XAIR Beyond Air

Beyond Air® to Announce Fiscal First Quarter 2021 Financial Results on Thursday, August 6th

Beyond Air® to Announce Fiscal First Quarter 2021 Financial Results on Thursday, August 6th

Conference call at 8:30 a.m. ET

GARDEN CITY, N.Y., July 23, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO for the treatment of solid tumors, today announced it will report financial results for its fiscal first quarter ended June 30, 2020 before the market opens on Thursday, August 6, 2020. The Company’s management team is scheduled to host a conference call and webcast at 8:30 a.m. Eastern Time.

Conference Call & Webcast Details:
Date and Time:Thursday, August 6th @ 8:30 a.m. ET
Domestic:888-220-8474
International:323-794-2590
Passcode:7088663
Webcast:

About Beyond Air, Inc.

Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company developing a revolutionary NO Generator and Delivery System, the LungFit™, that uses NO generated from ambient air to deliver precise amounts of NO to the lungs of ventilated and non-ventilated patients for the potential treatment of a variety of pulmonary diseases. The LungFit™ can generate up to 400 ppm of NO, for delivery either continuously or for a fixed amount of time and has the ability to either titrate dose on demand or maintain a constant dose. The Company is currently applying its therapeutic expertise to develop treatments for pulmonary hypertension in various settings, in addition to treatments for respiratory tract infections that are not effectively addressed with current standards of care. Beyond Air is currently advancing its revolutionary LungFit™ in clinical trials for the treatment of severe lung infections such as SARS-CoV-2, bronchiolitis and nontuberculous mycobacteria (NTM).  Additionally, Beyond Air is using ultra-high concentrations of NO with a proprietary delivery system, separate from the LungFit™, to target certain solid tumors in the pre-clinical setting.  For more information, visit .

CONTACT

Steven Lisi, Chief Executive Officer

Beyond Air, Inc. 

 

Corey Davis, Ph.D.

LifeSci Advisors, LLC

    

(212) 915-2577

EN
23/07/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Beyond Air

 PRESS RELEASE

Beyond Air® Reports Fiscal First Quarter 2026 Financial Results and Pr...

Beyond Air® Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update Increased revenues by 157% to $1.8 million, compared with $0.7 million for the fiscal quarter ended June 30, 2024 Awarded a national group purchasing agreement for therapeutic gases by Premier, Inc., which has more than 4,350 member hospitals and health systems in its network Reaffirm revenue guidance of $12-$16 million for the full fiscal year 2026 Conference call at 4:30 p.m. ET today, August 12th    GARDEN CITY, N.Y., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAI...

 PRESS RELEASE

Beyond Air Schedules First Fiscal Quarter 2026 Financial Results Confe...

Beyond Air Schedules First Fiscal Quarter 2026 Financial Results Conference Call and Webcast GARDEN CITY, N.Y., July 25, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that it will report financial results for its first fiscal quarter ended June 30, 2025 on Tuesday, August 12, 2025. The Company's management team is scheduled to host a conference call and webcast at 4:30 pm Eastern T...

 PRESS RELEASE

Beyond Air Awarded Therapeutic Gases Agreement with Premier, Inc.

Beyond Air Awarded Therapeutic Gases Agreement with Premier, Inc. GARDEN CITY, N.Y., July 22, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, has been awarded a national group purchasing agreement for therapeutic gases with Premier, Inc. Effective July 15th, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for the...

 PRESS RELEASE

Beyond Air® Reports Fourth Quarter and Full Year 2025 Financial Result...

Beyond Air® Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update Revenues increased 220% to $3.7 million, compared with $1.2 million for the fiscal year ended March 31, 2024 Expect to report revenue of at least $1.7 million for quarter ending June 30, 2025, and introducing revenue guidance of $12-$16 million for the full fiscal year 2026 Submitted PMA supplement for second-generation LungFit® PH to FDA International distribution partnerships now provide access to markets representing over 2 billion lives, with LungFit® PH actively shipping to Europe,...

 PRESS RELEASE

Beyond Air Submits FDA PMA Supplement for Next Generation LungFit® PH

Beyond Air Submits FDA PMA Supplement for Next Generation LungFit® PH LungFit PH II’s smaller, lightweight, transport-ready design is expected to open the entirety of the NO market Final design based upon substantial feedback from respiratory therapists across the country GARDEN CITY, N.Y., June 16, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced the submission of a premarket app...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch